Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT04061408 | FSRT in Breast Cancer Patients With Brain Metastases | unknown | Phase 2 | 170 | Fudan UniversityOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT01907529 | A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer(TENDENCY) | unknown | Phase 2 / Phase 3 | 300 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT04034823 | KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer | unknown | Phase 2 | 59 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 26, 2019 | clinicaltrials |
| NCT04033172 | Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )(Pyrotinib) | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT04012918 | Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study(CONCEPT) | unknown | Phase 2 | 124 | Ain Shams UniversityOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT03997539 | A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 256 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2019 | clinicaltrials |
| NCT03993964 | Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer | unknown | Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 0 | Jun 21, 2019 | clinicaltrials |
| NCT02768415 | Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01372579 | Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03933982 | A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer(Pyrotinib) | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT00499525 | Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer | unknown | Phase 2 | 180 | Northwestern UniversityOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT03932526 | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer | unknown | Phase 2 | 184 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT03923166 | Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer | unknown | Phase 2 | 35 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03923179 | Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer | unknown | Phase 2 | 32 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03919253 | Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study | unknown | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 0 | Apr 18, 2019 | clinicaltrials |
| NCT03910712 | Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC(Pyrotinib) | unknown | Phase 2 | 250 | Peking Union Medical College HospitalOTHER | 0 | Apr 10, 2019 | clinicaltrials |
| NCT02592746 | A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | unknown | Phase 2 | 182 | Samsung Medical CenterOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03907098 | Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03881878 | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery | unknown | Phase 1 / Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03876587 | Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC | unknown | Phase 2 | 79 | Zhejiang Cancer HospitalOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT03750396 | Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer(CLEAR) | unknown | Phase 2 | 110 | Gangnam Severance HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03182634 | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial(plasmaMATCH) | unknown | Phase 2 | 1,150 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03518268 | Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor | unknown | Phase 1 / Phase 2 | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Jan 17, 2019 | clinicaltrials |
| NCT02447211 | Topical Doxepin for Radiation-induced Dermatitis | unknown | Phase 2 | 60 | Isfahan University of Medical SciencesOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02511301 | Circadian Thermal Sensing to Detect Breast Disease | unknown | Phase 1 / Phase 2 | 173 | Cyrcadia HealthINDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03775928 | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03735082 | Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 29 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT03696004 | Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt | unknown | Phase 2 / Phase 3 | 45 | Assiut UniversityOTHER | 1 | Oct 4, 2018 | clinicaltrials |
| NCT03692689 | Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | unknown | Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03688958 | Iodine Supplementation on Breast Cancer | unknown | Phase 2 | 120 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT03684863 | Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 26, 2018 | clinicaltrials |
| NCT02095743 | Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer(EPIC) | unknown | Phase 2 | 256 | Centre Henri BecquerelOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT02939274 | An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer | unknown | Phase 2 | 15 | Rogers Sciences Inc.INDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
| NCT02000193 | Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer(FANCY) | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT03175341 | Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer | unknown | Phase 1 / Phase 2 | 30 | Academic Emergency County Hospital SibiuOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT03566394 | Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy | unknown | Phase 2 / Phase 3 | 46 | British Columbia Cancer AgencyOTHER | 0 | Jun 25, 2018 | clinicaltrials |
| NCT03562390 | Irinotecan for Advanced and Metastatic Breast Cancer | unknown | Phase 2 | 124 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT03560856 | A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer(PALPETBIO) | unknown | Phase 2 | 54 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 18, 2018 | clinicaltrials |
| NCT03507465 | Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer | unknown | Phase 2 / Phase 3 | 290 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT03497702 | Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer(NeoChAI) | unknown | Phase 2 | 114 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 13, 2018 | clinicaltrials |
| NCT03491410 | Breast Cancer Active Surveillance, Alternative Option, Aspirin Included | unknown | Phase 2 / Phase 3 | 60 | Centro Hospitalar Lisboa OcidentalOTHER_GOV | 0 | Apr 9, 2018 | clinicaltrials |
| NCT03429972 | Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients | unknown | Phase 2 | 51 | National Cancer Centre, SingaporeOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT03457467 | Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer | unknown | Phase 2 | 30 | Yan LiOTHER | 0 | Mar 7, 2018 | clinicaltrials |
| NCT03412955 | A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes | unknown | Phase 2 | 14 | Tan Tock Seng HospitalOTHER | 2 | Feb 27, 2018 | clinicaltrials |
| NCT03444025 | Neoadjuvant Goserelin for Triple Negative Breast Cancer(NeoGONT) | unknown | Phase 2 | 180 | Kasr El Aini HospitalOTHER | 0 | Feb 23, 2018 | clinicaltrials |
| NCT02213991 | Intraoperative Radiotherapy for Korean Patients With Breast Cancer | unknown | Phase 2 | 215 | Gangnam Severance HospitalOTHER | 1 | Feb 15, 2018 | clinicaltrials |
| NCT02214004 | Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women(HERAKLES) | unknown | Phase 2 | 132 | Gangnam Severance HospitalOTHER | 1 | Feb 15, 2018 | clinicaltrials |
| NCT03423849 | The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy | unknown | Phase 2 / Phase 3 | 200 | Zhiyong YuOTHER | 0 | Feb 6, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2019source: clinicaltrials